Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (October 2021)

44 slides from Windtree Therapeutics's investor presentation, Oct 18, 2021

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics Company Overview Octob WINDTREE THERAPEUTICS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company'

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights G Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ; WINT) G Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths: *

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline SI @ Lead Products FDA Fast Track Istaroxime Designation _(Acute Heart Failure) Potential for Istaroxime Breakthrough (Early Cardiogenic Shock) designation Oral SERCA2a Activators (Chronic HF; potentially HFpEF) FDA, EMA KL4 Surfactant—COVID 19 Orphan Drug for (COVID 1

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation To be updated once fullassessment of potential Planned Milestones COVID-19impactto trial conductis fuly understood Istaroxime Meet w/FDA Early Cardiogenic Shock Study 4 Data) )--“ an Istaroxime ae Acute Heart Failure Study EOP? Miginto {transition to Phase 3)** Pha, poten

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shock

  7. Slide 7: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MUSS., 20M+ worldwide patients > #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) > In-patient

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need "= Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g., “dry out”) with IV diuretics * Improve cardiac function and peripheral/organ perfusion * Achieve stable, fully compensated clinical

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism | of Action > ~ Oss, = Inhibition of the sodium- Stimulation of SERCA2a activity enhances calcium reuptake resulting in potassium pumpandeff

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients m bh © n=120 Dosing= 6 hour Phase ADHF Patients 0.5, 1, 1.5 ug/kg/min Infusion 2a Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/Wg/min Infusion (dyspnea plus need f

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio“ and Stroke Volume istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo 20 a 10 10 oo 00 10 10 g 2 g $20 B20 Pen ye 30 ‘0 Fe 3 50 so Infusion period Tafusion period ° . _ Pp * p-value = 0.029 * prvalues 0.034 Beene — Sho

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 2 Soo 9 z 7 — Systolic 5 Blood A Pressure = 6 + (SBP) é SE | 3 5 __TP-value=0.011, ** p-values0:006 ese organo yo oor eros roth =-9 Placeb

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 yg/kg/min vs. placebo x é 2 “ Infusion period a ee Eo 53 a 26 re) Ban * pwalue = 0.01 Sas sf SF S&S SS s a =-9- Placebo-Cohot 1 —geistaoxime0' ue/Ke/min cTnT —0 to 24 hours 36 9 2 OS wom istaroxime 1.0 g/kg/min vs. placebo Hea

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Clinically Significant Arrhythmias Clinically Significant Arrhythmias 120% —205% 105% 105% 35.0% 200% 2a0% 2a0% 100% aaiag ae 15.0% I 5% 60% fox foo% 100% = 3% 28% 20% P| 50% oom om Bxseine Oe

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Cardiogenic Shock

    Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf

  18. Slide 18: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an

  19. Slide 19: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat hypotension in the setting of shock(?) FDA Regulatory (Precedent: NDA for Gi

  20. Slide 20: Changes in SBP — Phase 2a and 2b Dose Groups

    Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 20.0 z 18.0 & 16.0 w 14.0 a + 12.0 & » 10.0 a § 8.0 & 60 & = 40 a 6 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study 0.5 pg/kg/min 1.0 yg/kg/min 1.5 yg/kg/min Study/Dose Mean SBP a

  21. Slide 21: Istaroxime Early Cardiogenic Shock Study

    Istaroxime Early Cardiogenic Shock Study Ongoing early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure 0 “60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF in the EU and US 1.0 - 1.5ug/kg/min target d

  22. Slide 22: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & iw. therapies for chronic heart = “Next generation Istaroxi

  23. Slide 23: Summary

    Summary Potential to Create Value = Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in Phase 2 or Phase 3 development for AHF treatment = Istaroxime— dual-mechanism therapy with positive Phase 2a and 2b trial outcomes: Y Improved cardiac functi

  24. Slide 24: Lyo Lucinactant

    Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients

  25. Slide 25: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function

    COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses angiotensin- ACEZissurfacemolecule on Surfactant is necessary for lungs to stay Increased likelihood of converting enzyme 2 alveolar Type 2 lung cells — inflated and for proper gas exchange; mechanical venti

  26. Slide 26: Surfactant Administration in Severe COVID-19 Lung Injury

    Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = Synthetic KL4 surfactant may mitigate surfactant deficiency wail and resist widespread surfactant destruction that can occur as a result of COVID-19 = Synthetic KL4 surfactant removes any im

  27. Slide 27: Phase 2 Study of Lucinactant for Treatment of COVID-19

    Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS * Up to 20 patients from 4-5 US sites and up to 4 sites in Latin America 7 °

  28. Slide 28: AEROSURF

    AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)

  29. Slide 29: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli

  30. Slide 30: AEROSURF — Potential to Impact the Clinical Course of RDS

    AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Long-Term Outcomes Reduced Rates and Severity of BPD GS winotRee we Noninvasive RDS treatment Improved Respiratory Study results show Parameters evidence of potential impact on clinical cour

  31. Slide 31: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach (1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: * Demonstrate that new ADS works and supplement Phase 2 data Optimize dosing with more drug and shorter repeat intervals Y Transitioned

  32. Slide 32: Financial Summary & Capitalization as of June 30, 2021

    Financial Summary & Capitalization as of June 30, 2021 = Cash & Equivalents of ~$30.0 million SZ windTREE Common Equivalents Securities as of June 30, 2021 Common Stock 26,704,456 Options (WAEP $11.30) 3,266,141 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 46,599,399 32

  33. Slide 33: Strategy for Value Generation

    Strategy for Value Generation Se we WINDTREE THERAPEUTICS” G Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts @& Transactions: * Secure focused BD transactions for deal revenue and

  34. Slide 34: Windtree Therapeutics

    Windtree Therapeuti “Striving to Deliver Hope for a Lifetime!” Se windTREE ue

  35. Slide 35: Appendix

    Appendix

  36. Slide 36: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  37. Slide 37: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- 1 cs E controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: * LVEF < 35% * SBP 90-150

  38. Slide 38: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events Pooled placebo {n=39) All adverse events 723 (59.0%) Adverse events leading to discontinuation 2G6%) Serious adverse events 2 (5.1%) Cardiogenic shock : Cardiac failure 4 (2.6%) Renal embolism : Transient ischemic attack 1 (2.6%) 4 (2.6%) 4 (2.6%) ‘Adverse Drug Rea

  39. Slide 39: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza ® Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur

  40. Slide 40: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic Demonstrated Utility of

  41. Slide 41: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange “4 Initial treatment options include £ 4 Penn seins = invasive and nonin

  42. Slide 42: Windtree Technology Platform — AEROSURF

    Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Liquid KLs surfactant (intratracheal instillate) for RDS approved by the FDA Lyophilized KLs surfactant currently being developed for AEROSURF Utilizing pressure and heated cap

  43. Slide 43: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® RISKS Surfactant Therapy Reversing surfactant deficiency has a profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia cord damage, asthma, lung damage ncPAP Respiratory

  44. Slide 44: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out

Windtree Therapeutics — Investor Presentation (October 2021) on 6ix